Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for epoetin alfa

  1. Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)

    Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.

    Technology appraisal guidance
    Published
    26 November 2014
    View recommendations

    Sections for TA323

  2. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]

    In development [GID-TA10877] Expected publication date: 20 November 2024

    Technology appraisal guidance
    In development

  3. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development [GID-TA10886] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)

    This guidance has been replaced by NICE technology appraisal guidance 323.

    Technology appraisal guidance
    Published
    28 May 2008